$ACB

Curaleaf launched an unsolicited offer to buy Aurora Cannabis for $272 million, or $4 per share, about a 45% premium to Aurora’s 30-day VWAP, aiming for about $1.5 billion revenue, $350 million adjusted EBITDA, and $40 million annual cost synergies. The article also discusses whether Canopy Growth could be a future acquisition target, citing its turnaround and global medical cannabis platform.

Curaleaf Holdings (CURLF) proposed a $4.00 per-share cash-and-stock takeover of Aurora Cannabis (ACB) after Aurora’s board declined to negotiate, offering a 45% premium to ACB’s 30-day VWAP of $2.75. ACB shareholders would receive 0.3463 CURLF shares plus $0.75 cash, with a $5 cap. Curaleaf cites $1.5B trailing revenue, ~$350M EBITDA, and $40M annual cost savings.

Curaleaf (OTC: CURLF) announced a hostile bid to acquire Aurora Cannabis (NASDAQ: ACB), saying Aurora has not engaged in negotiations. Curaleaf cites Aurora’s international footprint, including more than 50 tons of annual EU-GMP capacity, and estimates $40 million in annual cost synergies. Curaleaf says the offer is about $272 million and the combined business would have generated $1.5 billion revenue and $350 million EBITDA.

Curaleaf CEO Boris Jordan defended Curaleaf’s hostile $4.00 per share bid for Aurora Cannabis, saying Curaleaf sought a mutual NDA and exclusivity in late June before sending a July 7 letter to Aurora’s directors. Aurora formed a special committee to review the offer. The bid is mostly Curaleaf stock with a $5.00 cap. Curaleaf also denied allegations tied to an FBI probe reported by The Newsground.

Curaleaf Holdings said it plans a hostile takeover of Aurora Cannabis with a cash-and-stock offer implying US$4 per Aurora share. Aurora shareholders would get 0.3463 Curaleaf subordinate voting shares plus US$0.75 cash, a 45% premium to Aurora’s US$2.75 30-day VWAP. Curaleaf targets a 105-day offer after launch; Aurora disputes Curaleaf’s engagement claims and plans a special committee.

Curaleaf (CURLF) has launched a hostile takeover bid for Aurora Cannabis (ACB), saying Aurora has not engaged in talks. Curaleaf cites Aurora’s international footprint, including over 50 tons of EU-GMP capacity, and estimates $40M annual cost synergies. It targets a combined $1.5B revenue and $350M EBITDA, with an offer around $272M.

Curaleaf (CURLF) announced an unsolicited takeover bid for Aurora Cannabis (ACB) at $4 per share cash and stock, after private talks stalled. Curaleaf formed a special committee to review the offer and plans to take it to ACB shareholders. The article cites $1.5B annual revenue, $40M synergies, and ACB up on Aug. 11 but down ~10% YTD, with analysts’ targets up to $5.71.

Aurora Cannabis (ACB) reported Q1 fiscal 2027 net revenue of $67.6 million, with international medical cannabis up 17% while Canada consumer revenue declined. International net revenue was $43 million and 64% of total revenue came from outside Canada. Adjusted gross margin was 58%, adjusted EBITDA $3.4 million, cash nearly $150 million, and zero debt. The board formed a special committee to review Curaleaf’s unsolicited $4.00/share bid.

Curaleaf Holdings said it intends to launch a takeover bid for Aurora Cannabis at $4.00 per share, made up of 0.3463 Curaleaf shares plus $0.75 cash, implying a 45% premium to Aurora’s 30-day VWAP. Curaleaf cited >$1.5bn LTM revenue, ~$350m LTM Adj. EBITDA, and expects at least $40m annual cost synergies. No formal offer yet.

Curaleaf Holdings said it plans a hostile takeover of Aurora Cannabis, offering $4 per Aurora share in cash and Curaleaf stock, a 45% premium to Aurora’s 30-day VWAP (and 110% excluding balance sheet cash). Curaleaf said it first approached Aurora on June 23, 2026, and Aurora declined to engage. Aurora confirmed receiving letters and will form a special committee to review.